{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:17:52Z","timestamp":1783189072941,"version":"3.54.6"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate whether bioimpedance-derived body composition parameters are associated with adalimumab exposure and immunogenicity in noninfectious uveitis (NIU) and whether they provide information complementary to body mass index (BMI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Forty-five patients with NIU receiving adalimumab monotherapy (40 mg every 2 weeks) for at least 12 months were enrolled in this single-center cross-sectional study. Body composition was assessed by use of multifrequency bioimpedance analysis (InBody 770). Serum adalimumab trough concentrations and anti-adalimumab antibodies (AAA) were measured. Associations were evaluated using Pearson correlations, multivariable linear regression, and receiver operating characteristic (ROC) analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Adalimumab trough concentrations were moderately inversely correlated with BMI (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      = \u22120.51,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0004), body fat mass (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      = \u22120.51,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0004), percent body fat (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      = \u22120.48,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001), and visceral fat area (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      = \u22120.53,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0002), but not with lean-mass parameters. In separate multivariable models adjusted for age and sex, each adiposity measure was independently associated with trough concentrations (adjusted\n                      <jats:italic toggle=\"yes\">R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      0.18\u20130.25). ROC analysis showed comparable discrimination of low drug exposure for BMI (area under the curve [AUC] 0.69) and body composition metrics (AUC 0.70\u20130.74; DeLong\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.5). BMI showed the strongest correlation with AAA levels (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      = 0.58,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Bioimpedance-derived adiposity measures and BMI showed similar associations with adalimumab exposure in NIU. Body composition may offer complementary biological context for interpreting pharmacokinetic variability and immunogenicity. Future studies are warranted to determine whether body composition data improve therapeutic drug monitoring in uveitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10807683261466538","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:04:57Z","timestamp":1782968697000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Body Composition and Body Mass Index Show Comparable Associations with Adalimumab Exposure and Immunogenicity in Noninfectious Uveitis"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-4166","authenticated-orcid":false,"given":"Francesco","family":"Pichi","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada."},{"name":"Cleveland Clinic Abu Dhabi, Eye Institute, Abu Dhabi, United Arab Emirates."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rauda","family":"Shehab","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Abu Dhabi, Eye Institute, Abu Dhabi, United Arab Emirates."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Neri","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Abu Dhabi, Eye Institute, Abu Dhabi, United Arab Emirates."},{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.12.039"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.09.008"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.406"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204101"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.12.009"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.12.009"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12268"},{"issue":"4","key":"e_1_3_2_10_1","first-page":"F632","article-title":"Estimated lean body mass as an index for normalization of body fluid volumes in humans","volume":"247","author":"Boer P","year":"1984","unstructured":"9.Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol 1984;247(4 Pt 2):F632\u2013F6.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199426040-00005"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/11535960-000000000-00000"},{"issue":"1","key":"e_1_3_2_13_1","first-page":"145","article-title":"Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis","volume":"35","author":"Rosas J","year":"2017","unstructured":"12.Rosas J, , Llinares-Tello F, , Senabre-Gallego JM, , and the AIRE-MB Group. et al. Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis. Clin Exp Rheumatol 2017;35(1):145\u2013148.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.02.023"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.622468"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00522-0"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2020.94835"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu7125548"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2015.10.014"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021909-135846"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12509"},{"key":"e_1_3_2_24_1","first-page":"1396","article-title":"Effect of obesity on the response to tumor necrosis factor inhibitors in inflammatory bowel disease: A meta-analysis","volume":"113","author":"Singh S","year":"2018","unstructured":"23.Singh S, , Dulai PS, , Engelen E, et al. Effect of obesity on the response to tumor necrosis factor inhibitors in inflammatory bowel disease: A meta-analysis. Am J Gastroenterol 2018;113:1396\u20131404.","journal-title":"Am J Gastroenterol"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101623"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu10060738"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261466538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10807683261466538","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261466538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:49:50Z","timestamp":1783187390000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10807683261466538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":25,"alternative-id":["10.1177\/10807683261466538"],"URL":"https:\/\/doi.org\/10.1177\/10807683261466538","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"10807683261466538"}}